Novartis to pay $1 billion upfront to license Huntington’s drug from PTC

Taking stock of the drug industry, from the lab to the medicine chest

December 2, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Anna Yeo/STAT STAT+ | Novartis to pay $1 billion upfront to license Huntington's drug from PTC Novartis, which has previously tried to develop a Huntington's treatment, is licensing an experimental drug from PTC. By Andrew Joseph STAT+ | 'Significant talent shortage' threatens the rise of radiopharmaceuticals Among many drug developers and providers seeking to deliver radiopharmaceuticals to patients, there is a lack of expertise in the burgeoning field. By Allison DeAngelis STAT+ | Supreme Court tackles case involving FDA's oversight of flavored vapes If the FDA loses, the agency could decide to release fewer guidance documents, which give companies insight into its thinking. By Lizzy Lawrence Carlos Osorio/AP STAT+ | Big restaurant chains get an 'F' for antibiotic use in their meat supplies "Antibiotic resistance and the spread of superbugs is getting worse," said Steve Roach of Food Animal Concerns Trust. By Ed Silverman STAT+ | Former Trump FDA chief is seeking to undermine RFK Jr.'s Senate confirmation Gottlieb, who served in the first Trump administration, said RFK Jr.'s confirmation as HHS secretary would ultimately "cost lives in this country." By Rachel Cohrs Zhang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser